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Abstract 
Background and aims: Disordered gambling is a public health concern associated with 
detrimental consequences for affected individuals and social costs. Currently, opioid 
antagonists are considered the first-line treatments to reduce symptoms of uncontrolled 
gambling. Only recently, glutamatergic agents and combined pharmacological and 
psychological treatments have been examined appearing promising options for the 
management of gambling disorder. Methods: A multilevel literature search yielded 34 studies 
including open-label and placebo-controlled trials totaling 1,340 participants to provide a 
comprehensive evaluation of the short- and long-term efficacies of pharmacological and 
combined treatments. Results: Pharmacological treatments were associated with large and 
medium pre-post reductions in global severity, frequency, and financial loss (Hedges`s g: 
1.35, 1.22, 0.80, respectively). The controlled effect sizes for the outcome variables were 
significantly smaller (Hedges`s g: 0.41, 0.11, 0.22), but robust for the reduction of global 
severity at short-term. In general, medication classes yielded comparable effect sizes 
independent of predictors of treatment outcome. Of the placebo controlled studies, results 
showed that opioid antagonists and mood stabilizers, particularly the glutamatergic agent 
topiramate combined with a cognitive intervention and lithium for gamblers with bipolar 
disorders demonstrated promising results. However, more rigorously designed, large-scale 
randomized controlled trials with extended placebo lead-in periods are necessary. Moreover, 
future studies need to monitor concurrent psychosocial treatments, the type of comorbidity, 
use equivalent measurement tools, include outcome variables according to the Banff, Alberta 
Consensus, and provide follow-up data in order to broaden the knowledge about the efficacy 
of pharmacological treatments for this disabling condition. 
Keywords: gambling disorder, pharmacological treatment, meta-analysis 
 
 
PHARMACOLOGICAL TREATMENTS FOR DISORDERED GAMBLING        4 
 
Pharmacological Treatments of Disordered Gambling: A Meta-Analysis 
 
Disordered gambling is defined based on the criteria for substance use including 
preoccupation with maladaptive behaviors, lack of control, tolerance, withdrawal, and 
continued behavior despite negative consequences (DSM 5; American Psychiatric Association 
2013). Prevalence rates up to 5.8% worldwide (Calado and Griffiths 2016) indicate that 
problematic gambling is a public health concern associated with detrimental consequences for 
affected individuals in major areas of life (e.g., Raylu and Oei 2002) and social costs (e.g., 
Shaffer and Kidman 2004).  
In accordance with the different phenomenological perspectives initially 
conceptualizing gambling pathology as obsessive-compulsive spectrum disorder and finally as 
behavioral addiction, various medication classes have been investigated over the years (for 
reviews see Grant et al. 2014c; Lupi et al. 2014). In the light of similarities between 
uncontrolled gambling and substance use disorders (e.g., Rash et al. 2016), clinical 
examinations focused on opioid antagonists currently appearing most likely to reduce 
symptoms of disordered gambling (e.g., Bartley and Bloch 2013). Research on comorbidity 
(e.g., Dell'Osso et al. 2005) and genetic aspects such as family history of alcohol use disorder 
(e.g., Grant et al. 2008b) further stimulated the exploration of mood stabilizers, glutamatergic 
agents, and combined pharmacological and psychological treatments which seem promising 
for the management of gambling disorder (De Brito et al. 2017; Kovanen et al. 2016; 
Pettorruso et al. 2014). 
Although a number of systematic reviews have be conducted (e.g., Bullock and 
Potenza 2012), only three publications used meta-analytic strategies (Bartley and Bloch 2013; 
Leibetseder et al. 2011; Pallesen et al. 2007). The latest meta-analysis (Bartley and Bloch 
2013) was limited to placebo controlled trials, and to the single outcome variable “gambling 
severity”. Furthermore, the impact of study quality and other moderators on treatment 
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outcomes was not examined. Consequently, a comprehensive investigation of 
pharmacological treatment options for disordered gambling is still pending. 
The primary objective of the present meta-analysis was to investigate the efficacy of 
pharmacological treatments for disordered gambling for reducing the (a) global severity, (b) 
frequency, and (c) financial loss from gambling after treatment (short-term effects) and at the 
latest follow-up (long-term effects). Based on the latest state of research, we expected (1) 
mood stabilizers and glutamatergic medications to be equally effective as opioid antagonists 
(Pettorruso et al. 2014) and (2) combined pharmacological and psychological treatments to be 
more effective than pure pharmacological treatments (Huhn et al. 2014). In addition, our goal 
was to identify potential moderators of the effect sizes. The meta-analysis was conducted 
according to the recommendations of the PRISMA Statement (Moher et al. 2009). 
Methods 
Eligibility Criteria 
 
Studies were considered for inclusion if they (1) employed pharmacological, or 
combined treatments (e.g., pharmacological and psychological treatments applied at the same 
time); (2) used within-group, randomized, or quasi-randomized controlled study designs 
including a placebo intervention; (3) measured at least one of the outcome variables (i.e., 
global severity, frequency or financial loss); and (4) reported sufficient statistical data for 
effect size calculations. Studies were excluded if (1) the study was a single case study; (2) 
disordered gambling was secondary to Parkinson`s disease or to other medical conditions; (3) 
the study sample overlapped completely with the sample of another study included in the 
meta-analysis, or (4) no abstract or full text of the study was available. 
Information Sources and Literature Search 
We conducted a multilevel literature search using the databases PsycINFO, Medline, 
PubMed, Psyndex, the Cochrane Central Register of Clinical Trials, ProQuest Digital 
Dissertations, and the web search engine Google Scholar. The search covered all relevant 
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publications from the first available year until April 30, 2018 using the following disorder-
related search terms: “pathological gambling OR gambl* OR ludomania” combined with the 
intervention-related key words treatment “open-label OR placebo-controlled OR random* OR 
trial OR pilot”. Subsequently, we conducted a thorough examination of the reference lists of 
review articles, meta-analyses, and original studies retrieved from the databases. Additionally, 
authors of relevant articles were contacted to ask for unpublished papers suitable for inclusion 
in the meta-analysis. 
Outcome Measures 
Following the recommendations of the Banff, Alberta Consensus (Walker et al. 2006), 
we specified three outcome variables to measure the reduction of disordered gambling: a) the 
global severity of gambling pathology, quantified by the use of valid and reliable instruments 
such as the Yale-Brown Obsessive-Compulsive Scale adopted for disordered gambling (PG-
YBOCS; Pallanti et al. 2005), the Gambling Symptom Assessment Scale (G-SAS; Kim et al. 
2009), or South Oaks Gambling Screen (SOGS; Lesieur and Blume 1987) in order to facilitate 
the comparability of the effect sizes; if none of these measurement tools were available for 
this outcome variable, we used the score for the global gambling symptomatology of the 
Clinical Global Impression Scale (CGI; Guy 1976); (b) frequency of gambling (e.g., number 
of days or hours gambled last week or month), and (c) financial loss from gambling (e.g., 
money wagered last week or last month), both (b) and (c) quantified using a timeline follow-
up interview (Sobell and Sobell 1992), or other self-reporting forms. 
Study Selection 
Study selection was performed by two independent reviewers (the first and the second 
authors, MG and ML), and supervised by the last author of this paper (AL). Disagreements 
between the authors were resolved through discussion.  
Data Collection Process and Data Extraction 
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We generated a structured data extraction form that we refined and modified after pilot 
testing a sample of 10 studies. To calculate pre-post and pre-follow-up within-group effect 
sizes, numerical data were extracted for each outcome separately. If different pharmacological 
treatments were examined within one study, data for each condition was extracted separately 
and treated as single within-groups for statistical analyses. To calculate controlled effect sizes, 
posttreatment data from placebo control groups were included. Additionally, we extracted 
numerical and categorical data from each study in order to perform moderator analyses. Data 
extraction was performed by the first author (MG), and validated by the second author (ML). 
Disagreements were resolved by discussion. 
Risk of Bias in Individual Studies 
We assessed the internal validity of each study using the Quality Assessment Tool for 
Quantitative Studies, developed by the Effective Public Health Practice Project (EPHPP) 
(Thomas et al. 2004). This tool has demonstrated content and construct validity (Thomas et al. 
2004) and is recommended for systematic reviews and meta-analyses (Deeks et al. 2003). 
Each study was rated in a standardized manner on six domains: selection bias, study design, 
identification and control of confounders, blinding, reliability and validity of data collection 
tools, and reporting and percentage of withdrawals and dropouts. Each domain was evaluated 
as strong, moderate, or weak. The global rating was calculated after evaluation of the six 
domains. The first two authors (MG and ML) independently assessed each study and 
determined the global score of each trial. Interrater reliability was quantified using the kappa 
statistic. Disagreements between the authors were resolved through discussion until consensus 
was reached. 
Effect Size Calculation and Quantitative Data Synthesis 
Statistical analysis was performed using the software program Comprehensive Meta-
Analysis (CMA) version 2.2.064 (Borenstein et al. 2005). We calculated the effect sizes for 
the reduction of global severity, frequency, and financial loss separately for within-group and 
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controlled study designs (see Appendix for formulas). Due to small sample sizes, the effect 
sizes were corrected for bias using Hedges`s g with the corresponding 95% confidence 
interval (Hedges and Olkin 1984). If means and standard deviations were not available, effect 
sizes were calculated based on equivalent estimation procedures (e.g., t values, or exact 
probability levels). If an outcome variable was measured by more than one instrument, data 
from these instruments were entered separately and pooled together for the particular outcome 
variable (Lipsey and Wilson 2000). For studies reporting data based on both completers and 
ITT analyses, the ITT data was taken into account. The direction of the effect was adjusted 
according to the “success”: the effect size was positive if the treated group performed superior 
to the control group. According to Cohen’s recommendations (1977), effect sizes of 0.20 to 
0.30 can be classified as small, those near 0.50 as medium, and those above 0.80 as large. 
Assuming heterogeneity among the studies, we decided to use the random effects 
model for the integration of effect sizes. Heterogeneity of the effect sizes was investigated 
using the Q statistic with the corresponding p value, and the I2 statistic, indicating to what 
extent real differences in effect sizes was reflected by the proportion of the variance 
(Borenstein et al. 2009; Higgins et al. 2003). I2 values of 25%, 50%, and 75% were classified 
as low, moderate, and high, respectively (Higgins et al. 2003). 
Risk of Bias across Studies 
To control for publication bias, we conducted a thorough literature search and 
computed Rosenthal’s fail-safe N (Rosenthal 1979) and also examined funnel plots (Duval 
and Tweedie 2000). According to Rosenthal (1991), effect sizes are considered robust if the 
number of studies needed to obtain a nonsignificant overall effect is greater than 5k + 10, 
where k represents the number of studies. Additionally, we used the trim-and-fill method 
(Duval and Tweedie 2000) to estimate missing studies and their impact on the ascertained 
effect sizes. This method is based on the logic of the funnel plot and assumes a symmetrical 
distribution of the effect sizes for outcome variables in the absence of publication bias. In the 
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case of asymmetrical distribution, the trim-and-fill method adjusts and corrects the effect sizes 
(Borenstein et al. 2009); we only applied this method if 10 studies were available for the 
analysis (Sterne et al. 2011). Funnel plot asymmetry was assessed by using Egger`s test 
(Egger et al. 1997). As singular extreme effect size values produce misleading interpretations 
of treatment effects (Lipsey and Wilson 2000), we used the “one-study-removed” method 
offered by CMA to examine the impact of each study’s effect size on the overall effect 
(Borenstein et al. 2005). If the recalculated results did not substantially impact the effect size 
and remained within the 95% CI, studies were retained in the analyses. 
Moderator Analysis 
To explain heterogeneity among effect sizes, we determined the following categorical 
moderators: type of treatment (pharmacological vs. combined), dosage regimen (fixed vs. 
flexible), data analysis (intention-to-treat [ITT] vs. completer analysis), placebo lead-in phase 
(none vs. 1 week vs. > 1 week), type of gambling (electronic gambling vs. other types of 
gambling), quality of studies (EPHPP global scores), and the class of medication. The class of 
medication was analyzed by dividing pharmacological treatments into the following 
subcategories: (a) antidepressants (i.e., serotonin reuptake inhibitors [SSRI] including 
escitalopram/citalopram, fluvoxamine, sertraline, and paroxetine; norepinephrine-dopamine 
reuptake inhibitors [NDRI; e.g., bupropion]; serotonin-norepinephrine-dopamine reuptake 
inhibitors [SNDRI; e.g., nefazodone], and other antidepressants (e.g., agomelatine), (b) 
opioid-antagonists (e.g., nalmefene, naltrexone), (c) medications with mood-stabilizing 
potentials (e.g., lithium, topiramate, valproate, carbamazepine, olanzapine), and (d) other 
medications (e.g., acamprosate, N-acetylcysteine, memantine, tolcapone, ecopipam). Because 
mood disorders and anxiety were found to be associated with disordered gambling (e.g., Petry 
et al. 2005), and gender may influence treatment effects (Black et al. 2007a; Kim et al. 2001; 
Kim et al. 2002), we examined whether the effect sizes varied as a function of these 
moderators (inclusion vs. exclusion of mood disorders and/or anxiety, ≤ 50% males vs. > 50% 
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males). Moderator analyses for categorical variables were conducted using the mixed effects 
model with pooled estimates of T2 and the Q-test based on analysis of variance with the 
corresponding p value for the interpretation of the differences between subgroups (Borenstein 
et al. 2009). In the case of at least 10 available studies (Deeks et al. 2011), we further 
conducted meta-regression analyses using the year of publication and the duration of 
treatment (assessed with the number of weeks). Meta-regression analyses on the mean age 
were not performed because the age across studies differs from that within studies (Thompson 
and Higgins 2002). 
Results 
 
Study Selection 
A total of 39 studies including 43 treatment conditions were identified for inclusion in 
this meta-analysis. We excluded two studies assessed in recent reviews (Lupi et al. 2014; 
Pettorruso et al. 2014), because measurements were limited to the reduction of craving for 
gambling using VAS scores (Dannon et al. 2011; Zack and Poulos 2009), and thus the type of 
measurement tool did not satisfy the defined selection criteria. The flow diagram of the study 
selection process is illustrated in Figure 1. 
- Insert Figure 1 about here - 
Characteristics of Studies, Interventions, and Participants 
The present sample of studies varied in type of control condition: Studies implemented 
placebo control groups (49%), no control groups (43%), or other active treatment 
comparisons (8%). The minority of the studies implemented a placebo lead-in phase (26%), 
and provided follow-up data (10%) with periods ranging from one week to 12 months. Results 
were mainly based on completers (56%). 
Most trials examined antidepressants (44%), followed by opioid-antagonists (21%), 
mood stabilizers (21%), and other medications (14%) using a flexible dosage regimen (90%). 
Treatment duration ranged from 3 to 24 weeks (M = 11.69, SD = 4.59). 
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A total of 1,340 participants across all studies were analyzed. Of those, 864 were 
assigned to treatment conditions, 476 individuals to control groups. Because the majority of 
the studies excluded participants with severe Axis I/II disorders (94%), the average levels of 
co-occurring mood disorders and anxiety of the participants were subclinical. The total 
sample was predominantly male (66%) with an average age of 43 years. Although less than 
half of the studies indicated the type of gambling (39%), electronic gambling was the primary 
activity (73%). Detailed information regarding the characteristics of studies is presented in 
Table 1.  
- Insert Table 1 about here - 
Risk of Bias within Studies 
The global EPHPP scores for the studies are outlined in the Table 1. Validity 
assessment was conducted by two independent raters yielding an interrater reliability of κ = 
.84. 
Synthesis of Results and Risk of Bias across Studies 
The overall and the medication class-specific within-group and controlled effect sizes 
on all outcomes at posttreatment and follow-up, the 95% CI, and the significance tests are 
shown in Table 2. Results of the within-group and controlled effect sizes and their forest plots 
are presented in Figure 2. 
- Insert Figure 2 about here - 
Effect Sizes of Within-Group Study Designs at Posttreatment and Follow-up 
At posttreatment, the overall and medication-class-specific effect sizes were 
significant ranging from medium to large for the outcome variables. At follow-up, the overall 
analyses revealed significant results with a large effect size for the reduction of global 
severity. Follow-up data for the remaining outcome variables was based on single trials 
precluding the interpretation of long-term effect sizes. As depicted in Table 2, I2 values 
suggested predominantly high variability across the studies beyond sampling error. The trim-
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and-fill method identified 7 studies causing funnel plot asymmetry for the reduction of global 
severity (Egger`s test, p <.01), and 5 studies for the reduction of frequency (Egger`s test, p 
<.01). Accounting for the asymmetry of the funnel plot by filling in studies suggested a 
slightly reduced effect size for the reduction of global severity (g = 1.11; 95% CI [0.87, 
1.34]), and a reduced effect size for the reduction of frequency (g = 0.74; 95% CI [0.33, 
1.15]), suggesting small publication bias. No indication for publication bias was found for the 
reduction of financial loss (Egger`s test p = .045). The fail-safe N analyses performed for the 
available data suggested the robustness of the effect sizes, except for the reduction of financial 
loss among opioid antagonists, mood stabilizers and other medications which were not robust. 
Although one study (Egorov 2017) produced very large effect sizes in terms of all 
outcome variables (see Fig. 2), outlier identification through the one-study-removed 
procedure showed no impact of any single study on the overall effects or on the between-
study heterogeneity. 
Effect Sizes of Controlled Study Designs at Posttreatment and Follow-up 
At posttreatment, the overall and medication-class-specific effect sizes ranged from 
negative to medium. Only the overall effect sizes were significant and medium for the 
reduction of global severity, and small for the reduction of financial loss. Among the 
medication classes, opioid antagonists and mood stabilizers produced significant and medium 
effect sizes for the reduction of global severity. For mood stabilizers, a significant and 
medium effect size was also observed for the reduction of financial loss. Follow-up data was 
based on single trials precluding the interpretation of long-term effect sizes. I2 values 
suggested predominantly low variability across the studies beyond sampling error. No 
indication for publication bias was found for the reduction of global severity (Egger`s test p = 
.288). The fail-safe N analyses performed for the available data suggested the robustness only 
for the overall effect size for the reduction of global severity. The remaining effect sizes were 
not robust.  
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- Insert Table 2 about here -  
Moderator Analyses 
Moderator analyses were conducted on the overall and medication-specific effect 
sizes. The results of categorical variables are presented in the Table 3.  
The effect sizes across both study designs were not moderated by the type of 
treatment, the type of data analysis, placebo lead-in phase, the type of gambling, and 
treatment duration. Considering within-group study designs, significantly larger effect sizes 
were found for studies using flexible compared to fixed dosage regimen, and for those 
published more recently with respect to the reduction of global severity (β = 0.06; SE = 0.02; 
p < .01). Within the medication classes, agomelatine showed significantly larger effect sizes 
compared to other antidepressants in regards of all outcome variables.  
In controlled study designs, lithium showed an advantage over other mood stabilizers 
for the reduction of global severity. This result, however, was based on a single trial that 
included individuals with bipolar disorders (Hollander et al. 2005a) impacting the moderator 
“comorbid mood disorders/anxiety” accordingly. Similarly, one trial recruiting predominantly 
female participants (Kim et al. 2002) produced a larger effect size compared to those 
including mainly male participants among antidepressants. 
- Insert Table 3 about here - 
Discussion 
The objective of this paper was to investigate the efficacy of pharmacological 
treatments for disordered gambling and to identify possible predictors of treatment outcome. 
Results from within-group study designs revealed that pharmacological treatments effectively 
reduced the global severity and financial loss from gambling at short-term. We also 
ascertained a strong effect size for the reduction of frequency; however, the result from the 
trim-and-fill analysis indicated asymmetry in the underlying study sample. Although this 
could be caused by publication bias, it is more reasonable to assume that funnel plot 
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asymmetry arose from between-study heterogeneity (Egger et al. 1997; Sterne et al. 2001). 
Furthermore, the robustness of the treatment effect to reduce gambling frequency is supported 
by the fail-safe N analysis. Treatment success for the reduction of global severity remained 
stable over longer periods; however no firm conclusions can be drawn on the long-term gains 
of pharmacological treatments for the remaining outcome variables due to the limited amount 
of data. Similar levels of short-term effect sizes and the lack of catamnestic data were 
reported in previous meta-analyses in this area (Leibetseder et al. 2011; Pallesen et al. 2007). 
Direct comparisons with the present meta-analysis, however, are problematic because effect 
sizes were pooled across within-group and controlled study designs.  
As expected, inferior results for medications were observed in controlled study 
designs suggesting high rates of placebo responses. A number of reasons might account for 
these findings. First, mediators such as the therapeutic alliance established by regular contacts 
between patients and therapists, patients` expectations to benefit from treatment, learning 
processes associated with drug stimuli (classical conditioning), elevated levels of motivation 
to change problematic behavior, or the natural recovery from gambling, all aspects which are 
extensively discussed in the literature (e.g., Finniss et al. 2010; Grant and Chamberlain 2017; 
Prochaska et al. 1992; Schedlowski et al. 2015; Slutske 2006), may have contributed to the 
small between-group differences. Alternatively, additional support (i.e., keeping diaries, 
participation in Gamblers Anonymous groups, or self-help programs) which was either 
recommended or not monitored in some trials may have influenced the treatment effects. 
Despite these limitations, we ascertained significant medium and small benefits of 
medications relative to placebo for reducing the global severity and financial loss from 
gambling. Except for the overall effect size for the global symptom severity, however, our 
results should be interpreted with caution due to the lack of robustness demonstrating the need 
for further research. Nevertheless, the magnitude of the effect for the global symptom severity 
corresponds to that found for a variety of medical diseases and mental health disorders 
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revealing a median of all effect sizes of 0.40 (Leucht et al. 2012). As observed across both 
study designs, the implementation of short, one-week placebo lead-in phases did not affect 
treatment response. In the light of an early and high placebo effect observed for disordered 
gambling (Hollander et al. 2000; Hollander et al. 1998), more extended run-in phases may 
lead to a more effective identification of placebo responders. 
Moderator analyses indicated a small and nonsignificant advantage of combined 
treatments over pharmacotherapy alone for the reduction of global severity in within-group 
study designs and the reduction of financial loss in controlled study designs partially 
supporting our hypothesis. Although our findings were based on a limited number of 
combined trials, they agree with the tendency found in a recent review of meta-analyses on a 
range of medical diseases and disabling conditions (Huhn et al. 2014). With regard to the 
limitations of placebo controlled designs, it should be noted that particularly combined 
treatments examining medications along with psychotherapies which were equally provided 
to the placebo groups appear susceptible for masking the drug effect (Kovanen et al. 2016). 
Therefore, separate treatment groups receiving medication and psychotherapy alone compared 
with the combined treatment may help to disentangle the efficacies of the relevant treatment 
elements in upcoming studies (see also De Brito et al. 2017; Kovanen et al. 2016). 
Improvement was independent from treatment duration and gambling type across both 
study designs. The latter finding agrees with that reported in meta-analyses on psychological 
treatments for disordered gambling (Gooding and Tarrier 2009; Goslar et al. 2017) suggesting 
that all gamblers may share common mechanisms of addiction which were reduced during 
treatment. Moreover, individuals with and without co-occurring mood disorders and/or 
anxiety benefited to a comparable degree from treatment underscoring the conclusions of a 
recent review (Dowling et al. 2016). Only lithium appeared to be most effective for gamblers 
with bipolar disorder (Hollander et al. 2005a) supporting the treatment algorithm for this 
subgroup of individuals (Bullock and Potenza 2012). Given the preliminary nature of these 
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results, future studies should systematically investigate and report the types and rates of co-
occurring disorders in order to identify subgroups of gamblers, and to determine the impact of 
comorbidity on treatment outcomes (Dowling et al. 2016). Similarly, we found no advantage 
of any medication class over the other in reducing symptoms of disordered gambling across 
both study designs (see also Bartley and Bloch 2013; Pallesen et al. 2007). Regarding within-
group study designs, however, agomelatine outperformed SSRIs, SNDRI and NDRI. This 
novel antidepressant that promotes the resynchronization of circadian rhythms by acting on 
melatonin and 5-HT2c receptors (Le Strat and Gorwood 2008) produced promising results in 
the treatment of mood, anxiety, and a range of other disorders (for a review see De Berardis et 
al. 2015). Since our findings were based on a single trial including a small number of 
participants (Egorov 2017), further research is required to substantiate the efficacy of 
agomelatine for the treatment of disordered gambling. The particularly large effect size of this 
study and the beneficial gains of recently published treatments on topiramate (De Brito et al. 
2017), naltrexone (Kovanen et al. 2016), N-acetylcysteine (Grant et al. 2007; Grant et al. 
2014b), and ecopipam (Grant et al. 2014a) may have caused the positive association between 
outcome and year of publication and the superiority of flexible over fixed dosage regimen for 
the reduction of global severity. Although a slight advantage for flexible dosage was found for 
the remaining outcome variables, results should be interpreted with caution and warrant 
further research. 
Also in line with the current state of knowledge emphasizing opioid antagonists as the 
most supported drug treatment for gambling disorder (Bartley and Bloch 2013; Bullock and 
Potenza 2012), we ascertained a significant and medium advantage of opioid antagonists over 
placebo for the reduction of global severity. In contrast to Bartley and Bloch (2013), however, 
who found substantial heterogeneity across the studies and an effect size being flawed by the 
type of data analysis and the year of publication, our analyses revealed between-study 
homogeneity with no moderators impacting the effect size for opioid antagonists. These 
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differences may be based on the fact that Bartley and Bloch (2013) pooled effect sizes across 
scales with different contents (i.e., global severity, frequency and financial loss were 
subsumed under the single outcome variable “gambling severity”), and across varying 
measurement tools. Therefore, future studies and meta-analyses are encouraged to select 
equivalent response measures and differentiate between distinct aspects of gambling 
behaviors as recommended by the Banff, Alberta Consensus (Walker et al. 2006) in order to 
collect more information about the impact of treatment on frequency and financial loss from 
gambling, and to facilitate comparisons across the studies (for a review see Pickering and 
Keen 2018). Besides opioid antagonists which proved effective not only for the treatment of 
alcohol dependence (e.g., Jonas et al. 2014), but also for behavioral addictions other than 
disordered gambling (for a review see Mouaffak et al. 2017), we observed significant 
superiority of mood stabilizers over placebo supporting our hypothesis. It should be noted, 
however, that these results were driven by single trials which produced strong effects 
including either gamblers with bipolar disorders treated with lithium (Hollander et al. 2005a), 
or those treated with topiramate coupled with a brief cognitive intervention (De Brito et al. 
2017; see Fig. 2 for the reduction of financial loss). In addition to topiramate, other 
glutamatergic agents such as N-acetylcysteine and acamprosate which are favorable treatment 
options for substance use disorders (Guglielmo et al. 2015; Minarini et al. 2017; Witkiewitz et 
al. 2012), produced promising results in noncontrolled trials for disordered gambling (Black 
et al. 2011; Grant et al. 2007). Since medications targeting glutamatergic pathways not only 
appear to reduce symptoms of craving, but may also enhance cognitive flexibility as 
demonstrated by the use of memantine (Grant et al. 2010a), these types of drugs seem 
promising for investigation in further controlled study designs (Pettorruso et al. 2014). 
Relative to placebo, antidepressants reduced the global symptom severity to a similar level 
compared to that of the remaining drugs. The lack to obtain a significant effect, however, may 
be due to the heterogeneity across the studies caused by a single trial that determined the 
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magnitude of the treatment response and differed from the others by yielding a large effect 
size and including a high percentage of female participants (Kim et al. 2002). Even though a 
variety of gender-specific differences were ascertained in clinical trials (e.g., Echeburua et al. 
2011), the impact of sex on treatment outcomes needs to be replicated. Moreover, 
antidepressants may act differentially for subgroups of gamblers with additional diagnoses 
other than mood disorders and/or anxiety which were not systematically assessed. For 
example, SSRIs may be beneficial for gamblers with obsessive-compulsive disorders, but not 
for individuals with attention-deficit/hyperactivity disorder (Hollander et al. 2005b) 
underpinning the need to investigate comorbid conditions (Dowling et al. 2016). 
Nevertheless, some limitations and implications for further research should be 
mentioned: First and foremost, our meta-analysis covered a small number of studies. 
However, the short-term within-group effect sizes, and the overall controlled effect size for 
the reduction of global severity were robust. Second, as is true for most meta-analytic 
reviews, the included studies differed in their methodological quality, although when 
addressed statistically, we did not observe a systematic bias in the effect sizes due to 
differences in the quality of the studies. It should be noted that none of the studies achieved 
the highest rating reflecting limited quality of evidence with respect to selection bias, high 
dropout rates, and—particularly regarding within-group study designs—to the identification 
and control of confounders, and blinding. As a result, rigorously designed, large-scale RCTs 
are necessary including extended placebo lead-in periods, the monitoring of additional 
psychosocial support, the type of comorbidity, the use of equivalent measurement tools, the 
reporting of outcome variables according to the Banff, Alberta Consensus (Walker et al. 
2004), and the provision of follow-up data in order to determine the efficacy of medications 
over the long-term. Although the amount of drug dosage has demonstrated to impact 
treatment outcome (e.g., Bloch, McGuire, Landeros-Weisenberger, Leckman, & Pittenger, 
2010), this moderator could not be addressed in the present meta-analysis, because the studies 
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often provided insufficient information. Furthermore, when this information was provided, the 
dosage often varied depending on the type of medication, complicating these analyses, which 
would have resulted in insufficient test power. Moreover, the dosage within each drug class 
usually showed little variation, further complicating these analyses (Thompson & Higgins, 
2002). Therefore, additional studies will be necessary to examine the impact of dosage on 
treatment outcome within the different drug classes. Moreover, separate data should be 
reported for participants who receive low, moderate or high doses of the relevant medication 
facilitating the comparability of dosage within each drug class.     
Despite these limitations, the results of the present meta-analysis suggest that a variety 
of medications are effective for the management of gambling behaviors. Focusing placebo 
controlled designs, opioid antagonists and mood stabilizers, particularly the glutamatergic 
agent topiramate combined with a cognitive intervention and lithium for gamblers with 
bipolar disorders demonstrated preliminary evidence for reducing the global gambling 
severity. Although further neurobiological and neuroimaging studies should promote a better 
understanding in the mechanisms underlying problematic gambling behavior (e.g., Bullock 
and Potenza 2012), it seems most important to investigate the reasons for the high placebo 
response rates (Grant and Chamblerain 2017) and the natural recovery (e.g., Cuijpers and 
Cristea 2015) in order to improve pharmacological treatments for disordered gambling. 
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Fig. 1 Flow diagram of the study selection process 
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(k  = 990) 
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Treatment not targeted (k = 115) 
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Articles selected for further screening  
(k  = 46) 
 
 
 
 
 
Studies excluded (k  = 7): 
 
Other than defined primary outcome variables (k  = 2) 
Sample overlapped completely with other included 
study (k  = 0) 
Insufficient statistical data provided (k  = 5) 
 
 
Studies included in the meta-analysis  
(k  = 39) 
 
 
 
 
 
Articles identified through database search and other resources (k = 2,338): 
 
PsycINFO (k = 288); Medline (k  = 185); Pubmed (k  = 340); Psyndex (k  = 11); Google Scholar (k = 
585); Cochrane Central Register of Clinical Trials (k = 565); ProQuest Dissertations (k  = 16);  
Manual search of published reviews and primary studies (k  = 348); Author contacts (k  = 0) 
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1. Within-group study designs
(a) Global severity
Medication class Study name Treatment g 95% CI z p RW
AD Black (2004) BUP 1.56 [0.87, 2.25] 4.45 0.00 6.53
Black et al. (2007b) ESC 2.04 [1.26, 2.82] 5.13 0.00 6.20
Dannon et al. (2005a) FLUV 0.11 [-0.37, 0.59] 0.45 0.66 7.24
Dannon et al. (2005b) BUP 2.82 [1.57, 4.06] 4.44 0.00 4.56
Dannon et al. (2005c) BUP 0.77 [0.30, 1.24] 3.20 0.00 7.26
Egorov (2015) AGOM 5.07 [3.81, 6.33] 7.89 0.00 4.51
Grant et al. (2003) PARO 0.88 [0.58, 1.18] 5.70 0.00 7.72
Grant and Potenza (2006) ESC 0.80 [0.33, 1.26] 3.38 0.00 7.30
Hollander et al. (1998) FLUV 0.37 [-0.08, 0.83] 1.60 0.11 7.31
Myrseth et al. (2011) ESC 0.60 [0.19, 1.01] 2.90 0.00 7.45
Pallanti et al. (2002a) NEF 1.13 [0.60, 1.67] 4.13 0.00 7.05
Ravindran and Telner (2002) PARO 0.35 [-0.24, 0.94] 1.17 0.24 6.88
Ravindran and Telner (2002) PARO+CBT 1.14 [0.49, 1.80] 3.43 0.00 6.66
Saiz-Ruiz et al. (2005) SER 1.66 [1.25, 2.08] 7.83 0.00 7.43
Zimmerman et al. (2002) CIT 2.83 [1.96, 3.69] 6.39 0.00 5.88
Subtotal AD 1.32 [0.91, 1.72] 6.41 0.00
OA Dannon et al. (2005c) NALT 0.76 [0.31, 1.21] 3.28 0.00 19.16
Grant et al. (2008) NALT 1.08 [0.83, 1.33] 8.50 0.00 22.93
Kim and Grant (2001) NALT 1.82 [1.19, 2.44] 5.69 0.00 15.82
Kovanen et al. (2016) NALT+SUPP 1.88 [1.53, 2.44] 10.38 0.00 21.09
Lahti et al. (2010) NALT+MI+Book 1.58 [1.22, 1.94] 8.57 0.00 20.99
Subtotal OA 1.41 [1.00, 1.82] 6.74 0.00
MST Berlin et al. (2011) TOP 1.49 [1.00, 1.97] 6.02 0.00 15.82
Black et al. (2008) CARB 1.81 [0.71, 2.91] 3.22 0.00 6.91
Dannon et al. (2005a) TOP 0.55 [0.11, 0.99] 2.44 0.01 16.70
De Brito et al. (2017) TOP+CBT 1.99 [1.32, 2.66] 5.83 0.00 12.34
Fong et al. (2008) OLAN 1.05 [0.46, 1.65] 3.49 0.00 13.71
Pallanti et al. (2002b) LIT 1.28 [0.86, 1.70] 5.98 0.00 17.18
Pallanti et al. (2002b) VAL 0.97 [0.56, 1.38] 4.63 0.00 17.35
Subtotal MST 1.23 [0.88, 1.58] 6.97 0.00
Other Black et al. (2011) ACAMP 1.23 [0.64, 1.81] 4.13 0.00 16.12
Grant et al. (2007) NAC 0.89 [0.55, 1.23] 5.16 0.00 19.63
Grant et al. (2010a) MEM 1.73 [1.29, 2.17] 7.67 0.00 18.21
Grant et al. (2013) TOLC 1.64 [1.14, 2.13] 6.51 0.00 17.47
Grant et al. (2014b) NAC+AART+ID+MI 2.54 [1.69, 3.39] 5.83 0.00 12.35
Grant et al. (2014a) ECO 2.03 [1.45, 2.61] 6.91 0.00 16.23
Subtotal Other 1.62 [1.16, 2.07] 7.01 0.00
Overall 1.35 [1.14, 1.57] 12.35 0.00
(b) Frequency
Medication class Study name Treatment g 95% CI z p RW
AD Black et al. (2007b) ESC 0.94 [0.41, 1.48] 3.44 0.00 20.39
Egorov (2015) AGOM 3.28 [2.43, 4.13] 7.54 0.00 17.90
Pallanti et al. (2002a) NEF 0.83 [0.35, 1.32] 3.37 0.00 20.75
Saiz-Ruiz et al. (2005) SER 2.44 [1.90, 2.98] 8.85 0.00 20.37
Zimmerman et al. (2002) CIT 1.26 [0.75, 1.77] 4.85 0.00 20.59
Subtotal AD 1.71 [0.91, 2.51] 4.18 0.00
OA Kim and Grant (2001) NALT 1.74 [1.17, 2.32] 5.96 0.00 29.09
Kovanen et al. (2016) NALT+SUPP 0.49 [0.20, 0.78] 3.30 0.00 35.55
Toneatto et al. (2009) NALT+CBT 0.38 [0.08, 0.68] 2.48 0.01 35.35
Subtotal OA 0.81 [0.19, 1.44] 2.55 0.01
MST Black et al. (2008) CARB 0.82 [0.08, 1.56] 2.18 0.03 23.19
De Brito et al. (2017) TOP 1.24 [0.73, 1.75] 4.81 0.00 49.09
Fong et al. (2008) OLAN 1.38 [0.71, 2.05] 4.02 0.00 27.72
Subtotal MST 1.18 [0.83, 1.54] 6.54 0.00
Other Black et al. (2011) ACAMP 0.58 [0.10, 1.06] 2.36 0.02 43.84
Grant et al. (2010a) MEM 1.06 [0.72, 1.41] 6.01 0.00 56.16
Subtotal Other 0.85 [0.38, 1.32] 3.54 0.00
Overall 1.22 [0.85, 1.59] 6.43 0.00
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(c) Financial loss
Medication class Study name Treatment g 95% CI z p RW
AD Black et al. (2007b) ESC 0.69 [0.19, 1.19] 2.73 0.01 16.93
Egorov (2015) AGOM 3.79 [2.82, 4.76] 7.69 0.00 14.15
Myrseth et al. (2011) ESC 0.22 [-0.16, 0.59] 1.12 0.26 17.45
Pallanti et al. (2002a) NEF 0.54 [0.10, 0.98] 2.38 0.02 17.18
Saiz-Ruiz et al. (2005) SER 2.15 [1.66, 2.64] 8.56 0.00 16.94
Zimmerman et al. (2002) CIT 0.55 [0.15, 0.95] 2.69 0.01 17.34
Subtotal AD 1.24 [0.47, 2.01] 3.16 0.00
OA Kim and Grant (2001) NALT 0.92 [0.50, 1.35] 4.25 0.00 26.54
Kovanen et al. (2016) NALT+SUPP 0.49 [0.20, 0.78] 3.30 0.00 37.08
Toneatto et al. (2009) NALT+CBT 0.34 [0.04, 0.63] 2.21 0.03 36.38
Subrtotal OA 0.55 [0.25, 0.85] 3.57 0.00
MST Black et al. (2008) CARB 0.99 [0.21, 1.77] 2.47 0.01 13.96
De Brito et al. (2017) TOP 0.53 [0.14, 0.93] 2.63 0.01 53.83
Fong et al. (2008) OLAN 0.67 [0.15, 1.19] 2.54 0.01 32.21
Subtotal MST 0.64 [0.35, 0.93] 4.29 0.00
Other Black et al. (2011) ACAMP 0.20 [-0.24, 0.63] 0.89 0.38 24.97
Grant et al. (2007) NAC 0.68 [0.36, 0.99] 4.19 0.00 36.70
Grant et al. (2010a) MEM 0.65 [0.34, 0.95] 4.18 0.00 38.33
Subtotal Other 0.55 [0.28, 0.81] 4.04 0.00
Overall 0.80 [0.52, 1.07] 5.66 0.00
2. Controlled study designs
(a) Global severity
Medication class Study name Treatment g 95% CI z p RW
AD Black et al. (2007a) BUP -0.09 [-0.71, 0.53] -0.28 0.78 16.80
Grant et al. (2003) PARO -0.04 [-0.50, 0.43] -0.15 0.88 20.26
Hollander et al. (2000) FLUV 0.32 [-0.27, 0.90] 1.07 0.28 17.52
Kim et al. (2002) PARO 1.29 [0.66, 1.93] 4.00 0.00 16.46
Ravindran and Telner (2002) PARO+CBT 0.23 [-0.81, 1.28] 0.43 0.66 9.76
Saiz-Ruiz et al. (2005) SER 0.50 [-0.003, 1.01] 1.95 0.05 19.20
Subtotal AD 0.37 [-0.04, 0.77] 1.76 0.08
OA Grant et al. (2006) NALM 0.60 [0.13, 1.08] 2.50 0.01 17.28
Grant et al. (2008) NALT 0.47 [-0.05, 0.99] 1.79 0.07 14.44
Grant et al. (2010b) NALM 0.38 [0.03, 0.73] 2.11 0.03 31.79
Kim et al. (2001) NALT 0.69 [0.10, 1.29] 2.28 0.02 10.97
Kovanen et al. (2016) NALT+SUPP 0.35 [-0.04, 0.74] 1.75 0.08 25.52
Subtotal OA 0.46 [0.26, 0.66] 4.55 0.00
MST Berlin et al. (2011) TOP 0.34 [-0.26, 0.94] 1.11 0.27 22.99
De Brito et al. (2017) TOP+CBT 0.38 [-0.32, 1.08] 1.06 0.29 20.06
Fong et al. (2008) OLAN 0.48 [-0.36, 1.33] 1.12 0.26 16.72
Hollander et al. (2005a) LIT 1.58 [0.76, 2.41] 3.78 0.00 17.09
McElroy et al. (2008) OLAN 0.10 [-0.50, 0.69] 0.32 0.75 23.14
Subtotal MST 0.53 [0.06, 0.99] 2.23 0.03
Other Grant et al. (2014b) NAC+AART+ID+MI -0.36 [-1.09, 0.36] -0.98 0.33 100
Subtotal Other -0.36 [-1.09, 0.36] -0.98 0.33
Overall 0.41 [0.22, 0.59] 4.27 0.00
(b) Frequencya
Medication class Study name Treatment g 95% CI z p RW
AD Black et al. (2007a) BUP 0.00 [-0.61, 0.62] 0.00 0.99 29.84
Blanco et al. (2002) FLUV 0.02 [-0.66, 0.70] 0.06 0.95 24.78
Saiz-Ruiz et al. (2005) SER 0.10 [-0.40, 0.60] 0.40 0.69 45.38
Subtotal AD 0.05 [-0.28, 0.39] 0.31 0.76
OA Kovanen et al. (2016) NALT+SUPP 0.02 [-0.36, 0.41] 0.13 0.90 66.11
Toneatto et al. (2009) NALT+CBT -0.05 [-0.59, 0.49] -0.20 0.85 33.89
Subtotal OA -0.001 [-0.32, 0.31] -0.009 0.99
MST De Brito et al. (2017) TOP+CBT 0.63 [-0.09, 1.34] 1.73 0.08 24.15
Fong et al. (2008) OLAN 0.04 [-0.79, 0.87] 0.09 0.93 17.89
Hollander et al. (2005a) LIT 0.54 [-0.19, 1.27] 01.45 0.15 23.01
McElroy et al. (2008) OLAN 0.08 [-0.52, 0.67] 0.25 0.80 34.95
Subtotal MST 0.31 [-0.04, 0.66] 1.73 0.08
Overall 0.11 [-0.08, 0.30] 1.12 0.26
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Fig. 2 Individual and overal effect sizes for each study design, medication class and outcome at posttreatment 
AART = Ask-Advise-Refer-Therapy; ACAMP = acamprosate; AD = antidepressants; AGOM = agomelatine; 
BUP = bupropion; CARB = carbamazepine; CBT = cognitive-behavioral therapy; CI = confidence interval; CIT 
= citalopram; ECO = ecopipam; ESC = escitalopram; FLUV = fluvoxamine; g = Hedges`s g; ID = imaginal 
desensitization; LIT = lithium; MEM = memantine; MI = motivational interviewing; MST = mood stabilizers; 
NAC = N-acetylcysteine; NALM = nalmefene;  NALT = naltrexone; NEF = nefazodone; OA = opioid 
antagonists; OLAN = olanzapine; PARO = paroxetine; RW = relative weight; SER = sertraline; SUPP = 
psychosocial support; TOLC = tolcapone; TOP = topiramate; VAL = valproate. 
a Data for “other medications” were not available. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
(c) Financial lossa
Medication class Study name Treatment g 95% CI z p RW
AD Black et al. (2007a) BUP 0.04 [-0.58, 0.65] 0.11 0.91 29.86
Blanco et al. (2002) FLUV 0.09 [-0.59, 0.77] 0.26 0.80 24.77
Saiz-Ruiz et al. (2005) SER 0.14 [-0.37, 0.64] 0.53 0.60 45.37
Subtotal AD 0.09 [-0.24, 0.43] 0.55 0.59
OA Kovanen et al. (2016) NALT+SUPP 0.33 [-0.06, 0.71] 1.65 0.10 59.22
Toneatto et al. (2009) NALT+CBT -0.12 [-0.66, 0.42] -0.43 0.67 40.78
Subtotal OA 0.15 [-0.28, 0.58] 0.67 0.51
MST De Brito et al. (2017) TOP+CBT 0.99 [0.25, 1.73] 2.63 0.01 35.00
Fong et al. (2008) OLAN 0.16 [-0.67, 1.00] 0.39 0.70 28.79
Hollander et al. (2005a) LIT 0.39 [-0.34, 1.11] 1.04 0.30 36.21
Subtotal MST 0.53 [0.05, 1.02] 2.18 0.03
Overall 0.22 [0.02, 0.43] 2.15 0.03
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Table 1  Characteristics of studies 
Study/Year 
 
Total 
Na 
 
Treatment group(s)(N)/ 
average dose/dosage 
regimen 
 
Control group (N) PLA 
lead-in 
(w) 
Duration 
(w) 
FU 
(m) 
Outcomes  
(assessment) 
Gambling 
Type/ 
MD/A  
(+/-)b/ 
% Males 
Data  
Analysis 
EPHPP 
Antidepressants           
Black (2004) 10 
 
Bupropion (10) 
100–300 mg/d/flexible 
None 0 8 None GS (PG-YBOCS) 
 
NA/- 
≤ 50% 
CO 3 
Black et al. (2007a) 39 Burpopion (18) 
324 mg/d/flexible 
PLA (21) 0 12 None GS (PG-YBOCS; 
G-SAS) 
FR (min/w) 
FL (money/w) 
NA/- 
> 50% 
ITT 3 
Black et al. (2007b) 
 
 
19 
 
Escitalopram (19) 
10-30 mg/d/flexible 
None 0 10 None GS (PG-YBOCS) 
FR (min/w) 
FL (money/w) 
NA/- 
> 50% 
CO 3 
Blanco et al. (2002) 
 
32 Fluvoxamine (15) 
100 mg/d (2 weeks) 
200 mg/d (rest of 
trial)/fixed 
PLA (17) 0 24 None FR (h/w) 
FL (money/w) 
NA/- 
> 50% 
ITT 3 
Dannon et al. 
(2005a) 
20 1) Topiramate (12) 
200 mg/d/fixed 
 
2) Fluvoxamine (8)c 
200 mg/d/fixed 
0 12 None GS (PG-YBOCS) 
 
NA/- 
> 50% 
CO 2 
Dannon et al. 
(2005b) 
12 Bupropion (12) 
300–450 mg/d/flexible 
None 0 12 None GS (PG-CGI) 
 
NA/- 
> 50% 
CO 3 
Dannon et al. 
(2005c) 
25 1) Bupropion (12)c 
300-450 mg/d/flexible 
2) Naltrexone (13) 
100 -150 mg/d/ 
flexible 
0 12 None GS (PG-YBOCS) 
 
NA/- 
> 50% 
CO 2 
Egorov (2017) 20 Agomelatine (20) 
25–50 mg/d/flexible 
None 0 8 None GS (PG-YBOCS) 
FR (h/w) 
FL (money/w) 
NA/+ 
> 50% 
CO 3 
Grant et al. (2003) 
 
71 Paroxetine (34) 
10-60 mg/d/flexible 
PLA (37) 1 16 
 
None GS (PG-YBOCS; 
G-SAS) 
NA/- 
> 50% 
ITT 2 
Grant and Potenza 
(2006) 
13 Escitalopram (13) 
10-30 mg/d/flexible 
None 1 11 
 
None GS (PG-YBOCS; 
G-SAS) 
E/+ 
> 50% 
ITT 3 
Hollander et al. 
(1998) 
10 Fluvoxamine (10) 
220 mg/d/flexible 
None 8 8 
 
None GS (PG-YBOCS) Other/+ 
> 50% 
CO 3 
Hollander et al. 
(2000) 
10 Fluvoxamine (4) 
195 mg/d/flexible 
PLA (6) 1 16 
 
None GS (PG-YBOCS) Other/- 
> 50% 
CO 2 
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Study/Year 
 
Total 
Na 
 
Treatment group(s)(N)/ 
average dose/dosage 
regimen 
 
Control group (N) PLA 
lead-in 
(w) 
Duration 
(w) 
FU 
(m) 
Outcomes  
(assessment) 
Gambling 
Type/ 
MD/A  
(+/-)b/ 
% Males 
Data  
Analysis 
EPHPP 
Kim et al. (2002) 
 
45 Paroxetine (23) 
 51.7 mg/d/flexible 
PLA (22) 1 8 
 
None GS (G-SAS) E/- 
≤ 50% 
ITT 2 
Myrseth et al. 
(2011) 
 
15 1) Escitalopram (15)d 
5-10 mg/d/flexible for 8w, 
followed by 
2) Escitalopram+8 sessions 
CBT for 8w 
3) CBT+MI (15)e 
None 0 8 6 GS (G-SAS) 
FL (money/w) 
 
E/- 
> 50% 
ITT 3 
Pallanti et al. 
(2002a) 
 
12 Nefazodone (12) 
345.83 mg/d/flexible 
None 0 8 None GS (PG-YBOCS) 
FR (episodes/w; 
min./episodes) 
FL (money/w) 
E/- 
> 50% 
CO 3 
Ravindran and 
Telner (2006) 
 
19 1) Paroxetine (5) 
10–60 mg/d/flexible 
2) Paroxetine 
10–60 mg /d/flexible+12 
sessions CBT (7) 
PLA+12 sessions 
CBT (7)f 
0 16 None GS (PG-YBOCS; 
G-SAS) 
 
NA/- 
> 50% 
CO 3 
Saiz-Ruiz  
et al. (2005) 
 
60 Sertraline (31) 
95 mg/d/flexible 
PLA (29) 0 24 None GS (SOGS) 
FR (gambling 
activity/w) 
FL (money/w) 
NA/- 
> 50% 
ITT 
 
2 
Zimmerman et al. 
(2002) 
 
15 Citalopram (15) 
34.7 mg/d/flexible 
None 0 12 None GS (PG-YBOCS) 
FR (days/w) 
FL (money/w) 
E/+ 
> 50% 
CO 3 
Opioid antagonists           
Dannon et al. 
(2005c) 
25 1) Bupropion (12) 
300-450 mg/d/flexible 
2) Naltrexone (13)g 
100 -150 mg/d/ 
flexible 
0 12 None GS (PG-YBOCS) 
 
NA/- 
> 50% 
CO 2 
Grant et al. (2006) 
 
 
73 1) Nalmefene  
25 mg/d (40) 
2) Nalmefene  
50 mg/d (29)h 
3) Nalmefene  
100 mg/d (33)/fixed 
PLA (44) 0 16 None GS (PG-YBOCS; 
G-SAS) 
NA/- 
> 50% 
CO 
 
3 
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Study/Year 
 
Total 
Na 
 
Treatment group(s)(N)/ 
average dose/dosage 
regimen 
 
Control group (N) PLA 
lead-in 
(w) 
Duration 
(w) 
FU 
(m) 
Outcomes  
(assessment) 
Gambling 
Type/ 
MD/A  
(+/-)b/ 
% Males 
Data  
Analysis 
EPHPP 
Grant et al. (2008) 77 Naltrexone  
50, 100, 150 mg/ i 
(58)/fixed 
PLA (19) 1 17 
 
None GS (PG-YBOCS; 
G-SAS) 
E/- 
≤ 50% 
 
ITT 2 
Grant et al. (2010b) 128 Nalmefene 20 mg 
Nalmefene 40 mg 
(57)h/fixed 
PLA (71) 1 3 None GS (PG-YBOCS; 
G-SASj) 
NA/- 
> 50% 
CO 3 
Kim and Grant 
(2001) 
 
17 Naltrexone (17) 
157 mg/d/flexible 
None 0 6 None GS (G-SAS) 
FR (episodes/w) 
FL (money/w) 
NA/- 
≤ 50% 
 
ITT 3 
Kim et al. (2001) 
 
45 Naltrexone (20) 
187.5 mg/d/flexible 
PLA (25) 1 11 
 
None GS (G-SAS) 
FR (episodes/w)  
NA/- 
≤ 50% 
CO 2 
Kovanen et al. 
(2016) 
101 Naltrexone/flexible 
50 mg in case of craving 
+3 sessions psychosocial 
support (50) 
PLA+3 sessions 
psychosocial support 
(51) 
0 20 None GS (PG-YBOCS) 
FR (days/w) 
FL (highest daily 
expenditure/w) 
E/- 
> 50% 
ITT 2 
Lahti et al. (2010) 39 Naltrexone/flexible 
50 mg in case of craving 
+1 MI+booklet (39) 
None 0 16 
 
None GS (PG-YBOCS) 
 
NA/- 
> 50% 
ITT 3 
Toneatto et al. 
(2009) 
 
52 Naltrexone 
100 mg/d/flexible 
+7 sessions CBT (27) 
PLA+7 sessions CBT 
(25) 
0 10 
 
12 FR (gambling 
activities/w) 
FL (money/w) 
Other/- 
> 50% 
ITT 2 
Mood stabilizers           
Berlin et al. (2011) 
 
42 
 
Topiramate (20) 
222.5mg/d/flexible 
PLA (22) 0 14 None GS (PG-YBOCS; 
G-SAS) 
NA/- 
≤ 50% 
ITT 
 
2 
Black et al. (2008) 
 
8 Carbamazepine (8) 
 675 mg/d/flexible 
None 0 10 
 
None GS (PG-YBOCS; 
G-SAS) 
FR (min/w) 
FL (money/w) 
NA/- 
> 50% 
CO 3 
Dannon et al. 
(2005a) 
20 1) Topiramate (12)k 
200 mg/d/fixed 
2) Fluvoxamine (8) 
200 mg/d/fixed 
0 12 None GS (PG-YBOCS) 
 
NA/- 
> 50% 
CO 2 
De Brito et al. 
(2017) 
30 Topiramate 
180.7 mg/d/flexible 
+4 sessions CR (15) 
PLA+4 sessions CR 
(15) 
0 12 None GS (PG-YBOCS; 
G-SAS) 
FR (h/m) 
FL (money/m) 
E/- 
> 50% 
CO 2 
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Study/Year 
 
Total 
Na 
 
Treatment group(s)(N)/ 
average dose/dosage 
regimen 
 
Control group (N) PLA 
lead-in 
(w) 
Duration 
(w) 
FU 
(m) 
Outcomes  
(assessment) 
Gambling 
Type/ 
MD/A  
(+/-)b/ 
% Males 
Data  
Analysis 
EPHPP 
Fong et al. (2008) 21 Olanzapine (9) 
2.5-10 mg/d/fixed 
PLA (12) 0 7 None GS (PG-CGI) 
FR (days/w) 
FL (money/d) 
E/- 
> 50% 
CO 2 
Hollander et al. 
(2005a) 
29 Lithium (12) 
 1.150 mg/d/flexible 
PLA (17) 0 10 None GS (PG-YBOCS) 
FR (episodes/w; 
min/episodes) 
FL (money/w) 
NA/+ 
> 50% 
CO 1 
McElroy et al. 
(2008) 
 
42 Olanzapine (21) 
2.5-15 mg/d/flexible 
PLA (21) 1 12 
 
None GS (PG-YBOCS) 
FR (episodes/w; 
h/w) 
NA/- 
≤ 50% 
ITT 2 
Pallanti et al. 
(2002b) 
42 1) Lithium (23) 
795.6 mg/d/flexible 
2) Valproate (19) 
873.7 mg/d/flexible 
0 14 None GS (PG-YBOCS) E/- 
> 50% 
ITT 2 
Other medications           
Black et al. (2011) 
 
19 Acamprosate (19) 
1.998 mg/d/fixed 
None 0 8 
 
None GS (PG-YBOCS; 
G-SAS) 
FR (min/w; 
episodes/w) 
FL (money/w) 
NA/- 
≤ 50% 
CO 3 
Grant et al. (2007) 
 
27 N-Acetylcystein (27) 
600–1.800 mg/d/flexible 
None 0 8 None GS (PG-YBOCS; 
G-SAS) 
FL (money/w) 
E/- 
> 50% 
ITT 3 
Grant et al. (2010a) 
 
29 Memantine (29) 
10-30 mg/d/flexible 
None 0 10 None GS (PG-YBOCS; 
G-SAS) 
FR (h/w) 
FL (money/w) 
E/- 
≤ 50% 
ITT 3 
Grant et al. (2013) 22 Tolcapone (22) 
100-300 mg/d/flexible 
None 0 8 None GS (PG-YBOCS; 
G-SAS) 
NA/- 
≤ 50% 
CO 
 
3 
           
Grant et al. (2014a) 22 Ecopipam/flexible (22) 
50mg in case of craving 
None 1 6 None GS (PG-YBOCS; 
G-SAS) 
NA/- 
> 50% 
CO 3 
Grant et al. (2014b) 28 N-Acetylcystein  
1.200-3.000mg/d/ 
flexible 
+AART+ID+MI (13) 
PLA+AART+ID 
+MI (15) 
0 12 3 GS (PG-YBOCS) 
 
NA/- 
> 50% 
ITT 2 
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Note. A = anxiety; AART = Ask-Advise-Refer-Therapy; BDI = Beck Depression Inventory; CBT = cognitive behavioral therapy; CO = completers only; CR = cognitive 
restructuring; d = day; E = electronic gambling; EPHPP = Effective Public Health Practice Project (quality assessment tool for quantitative studies); FL = financial loss; FR = 
frequency; FU = follow-up; GAS = Global Assessment Scale; GS = global severity; G-SAS = Gambling Symptom Assessment Scale; h = hours; ID = imaginal desensitization; 
ITT = intention-to-treat; m = month; MD = mood disorders; MI = Motivational Interviewing; min = minutes; NA = not available; PG-CGI = Clinical Global Impression for 
Pathological Gambling; PG-YBOCS = Pathological Gambling Adaptation of the Yale-Brown Obsessive-Compulsive Scale; PLA = placebo; SOGS = South Oaks Gambling 
Screen; SUPP = additional support; w = week. 
a Number of subjects included in the analysis. 
b Studies which included (+) or excluded (-) participants with comorbid MD and/or A. MD and/or A was determined based on the mean values for MD and/or A using the cut-off 
scores of the respective measurement tools. 
c The fluvoxamine and bupropion treatment arms were used for effect size calculations of antidepressants. 
d Only the first treatment condition was used for effect size calculations, because participants in the escitalopram and the escitalopram + CBT treatment conditions overlapped 
completely.  
e This treatment condition was excluded from the analyses due to the incompatibility with the selection criteria. 
f This control group was used as the comparison condition to calculate the controlled effect size for the combined treatment. 
g The naltrexone treatment arms was used for effect size calculations of opioid antagonists.  
h To ensure the comparability of nalmefene groups, data from 40mg or 50mg treatment arms were used for effect size calculations. 
i Only data for the combined treatment arms were reported. 
 j The G-SAS scale could not be used for effect size calculation due to insufficient statistical data. 
k The topiramate treatment arm was used for effect size calculations of mood stabilizers. 
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Table 2    Effect sizes for pharmacological treatments at posttreatment and follow-up 
 Outcome Effect k g 95% CI z p I2 FS N  k g 95% CI z p I2 FS N 
   Within-group study designs  Controlled study designs 
Overall GS post 33 1.35 [1.14; 1.57] 12.35 <.001 83.96*** 7,166  17 0.41 [0.22; 0.59] 4.27 <.001 44.48* 131 
  FU 3 1.63 [0.81; 2.44] 3.92 <.001 83.64** 65  1 1.31 [0.35; 1.91] 2.84 <.01 0.00 —b 
 FR post 13 1.22 [0.85; 1.59] 6.43 <.001 87.53*** 899  9 0.11 [-0.08; 0.30] 1.12 .264 0.00 —a 
  FU 1 0.47 [0.11; 0.82] 2.59 <.05 0.00 —b  1 -0.03 [-0.65; 0.59] -0.10 .924 0.00 —b 
 FL post 15 0.80 [0.52; 1.07] 5.66 <.001 85.13*** 685  8 0.22 [0.02; 0.43] 2.15 . <.05 0.00 2 
  FU 2 0.27 [0.01; 0.52] 2.07 <.05 0.00 —b  1 -0.18 [-0.81; 0.44] -0.58 .565 0.00 —b 
AD GS post 15 1.32 [0.91; 1.72] 6.41 <.001 87.94*** 988  6 0.37 [-0.04; 0.77] 1.76 .078 63.08* —a 
 FR post 5 1.71 [0.91; 2.51] 4.18 <.001 90.14*** 200  3 0.05 [-0.28; 0.39] 0.31 .759 0.00 —a 
 FL post 6 1.24 [0.47; 2.01] 3.16 <.01 93.57*** 159  3 0.09 [-0.24; 0.43] 0.55 .586 0.00 —a 
OA GS post 5 1.41 [1.00; 1.82] 6.74 <.001 82.70*** 341  5 0.46 [0.26; 0.66] 4.55 <.001 0.00 24 
 FR post 3 0.81 [0.19; 1.44] 2.55 <.05 88.82*** 33  2 -0.001 [-0.32; 0.31] -0.009 .993 0.00 —b 
 FL post 3 0.55 [0.25; 0.85] 3.57 <.001 59.53 22  2 0.15 [-0.28; 0.58] 0.67 .505 41.79 —b 
MST GS post 7 1.23 [0.88; 1.58] 6.97 <.001 65.87** 254  5 0.53 [0.06; 0.99] 2.23 <.05 54.35 10 
 FR post 3 1.18 [0.83; 1.54] 6.54 <.001 0.00 29  4 0.31 [-0.04; 0.66] 1.73 .084 0.00 —a 
 FL post 3 0.64 [0.35; 0.93] 4.29 <.001 0.00 13  3 0.53 [0.05; 1.02] 2.18 <.05 16.40 2 
Other GS post 6 1.62 [1.16; 2.07] 7.01 <.001 78.56*** 336  1 -0.36 [-1.09; 0.36] -0.98 .327 0.00 —b 
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 Outcome Effect k g 95% CI z p I2 FS N  k g 95% CI z p I2 FS N 
   Within-Group Study Designs  Controlled Study Designs 
 FR post 2 0.85 [0.38; 1.32] 3.54 <.001 60.98 —b  NA       
 FL post 3 0.55 [0.28; 0.81] 4.04 <.001 43.08 20  NA       
Note. AD = antidepressants; CI = confidence interval; FR = frequency; FL = financial loss; FS N = Fail-safe N (number of studies needed to obtain a nonsignificant treatment 
effect); FU = effect sizes from pretreatment to latest follow-up for within-group study designs, and from posttreatment to latest follow-up for controlled study designs; g = 
Hedges’s g; I2 = percentage of total variation across studies; GS = global severity; k = number of treatment conditions; MST = mood stabilizers; NA = not available; OA = opioid 
antagonists; Qbet = homogeneity statistic for differences between subgroups. 
a Fail-safe N was not calculated because p was not significant. 
b Fail-safe N was not calculated because less than three studies were available. 
* p < .05 
** p < .01 
*** p < .001 
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Table 3   Moderator analyses for categorical variables for pharmacological treatments 
 
   Within-group study designs Controlled study designs 
Moderator Outcome variable Qbet p(Q) Qbet p(Q) 
Treatment (Pharmacological, Combined) 
  GS 3.34 .067 1.39 
 
.239 
   FR 3.35 
 
.067 
 
0.00 
 
.938 
   FL 1.66 
 
.197 
 
0.52 .469 
Medication class (AD, OA, MST, Other) 
  GS 1.59 .663 3.32 .345 
   FR 4.31 .230 1.83 
 
.400 
   FL 3.24 .357 
 
2.62 .270 
AD Type (SSRI/SNDRI, NDRI, Agomelatine) 
  GS 20.97 <.001 0.93 .335 
  FR 4.80 <.05 0.04 .850 
  FL 11.09 <.01 
 
0.05 .825 
OA Type (Naltrexone, Nalmefene) 
 
 
 GS 0.00 1.00 0.01 .917 
   FR 0.00 1.00 0.00 1.00 
  FL 0.00 1.00 0.00 1.00 
MST Type (Carbamazepine, Lithium, Olanzapine, Topiramate, Valproate) 
 
 
 GS 0.65 .958 8.21 <.05 
   FR 0.04 .982 2.16 .339 
  FL 0.11 .946 2.39 .302 
Other Type (Acamprosate, Ecopipam, Memantine, N-Acetylcysteine, Tolcapone) 
 
 
 GS 0.25 .993 0.00 1.00 
   FR 2.56 .109 NA NA 
  FL 3.51 .173 NA NA 
Dosage regimen (Fixed, Flexible) 
  GS 5.01 <.05 0.18 .671 
  FR 0.32 .572 0.11 
 
.742 
   FL 1.04 .309 0.17 .679 
 Data analysisa (CO, ITT) 
  GS 0.009 .923 1.86 .172 
  FR 0.03 .873 1.67 
 
.102 
   FL 0.11 .741 2.50 
 
.114 
 Placebo lead-in (None, 1 week, 8 weeks) 
  GS 3.31 .191 0.04 .850 
  FR 1.88 .171 0.34 .559 
   FL 0.82 .366 1.79 
 
.181 
 Type of gamblingb (Electronic, Other) 
  GS 3.38 .066 0.40 .527 
  FR 0.89 .346 0.59 .442 
  FL 1.38 .241 1.77 .183 
EPHPP (1, 2, 3) 
  GS 1.99 
 
.158 0.25 .619 
  FR 0.09 .764 0.22 .642 
  FL 0.00 .972 0.61 .434 
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   Within-group study designs Controlled study designs 
Moderator Outcome variable Qbet p(Q) Qbet p(Q) 
Comorbid MD/A (Included, Excluded) 
  GS 1.88 .171 
 
6.98 
 
<.01 
   FR 0.53 .468 0.06 .811 
  FL 1.68 .195 0.66 .415 
% Males (≤ 50%, > 50%) 
  GS 0.46 
 
.498 
 
1.15 
 
.284 
    AD 0.09 .759 10.18 <.01 
  FR 0.09 
 
.770 
 
0.01 .905 
  FL 0.55 .458 
 
0.00 1.00 
Note. Moderator analyses were conducted on the overall and medication-specific effect sizes. Only if moderator 
analyses on the medication-specific effect sizes differed from those on the overall effect sizes, results were 
reported separately. A = anxiety; AD = antidepressants; CO = completers; EPHPP = Effective Public Health 
Practice Project (quality assessment tool for quantitative studies); FR = frequency; FL = financial loss; GS = 
global severity; ITT = intention-to-treat analysis; MD = mood disorders; MST = mood stabilizers; NA = not 
available; NDRI = norepinephrine-dopamine reuptake inhibitor; OA = opioid antagonists; Qbet = homogeneity 
statistic for differences between subgroups; SSRI = serotonin reuptake inhibitor; SNDRI = serotonin-
norepinephrine-dopamine reuptake inhibitor.  
a The study of Black et al. (2004) was excluded, because no information regarding the data analysis was 
available. 
b Only studies which reported the type of gambling were included in the analyses. 
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Appendix 
Formulas for the Effect Size Calculations  
To compute the within-group effect sizes, the following formulas were utilized (Borenstein et 
al. 2005, 2009):  
d = , 
such that !"1 reflects the pretreatment mean, !"2  reflects the post-treatment mean, Sdifference 
reflects the standard deviation of the difference, and r reflects the correlation between 
pretreatment and posttreatment scores. Following Rosenthal (1991), we estimated the pre-post 
correlation to be r = .70. Due to small sample sizes, all effect sizes were corrected for bias 
using Hedges’s g which was computed by multiplying d with the correction factor 
J(df) = , 
such that df represents the degrees of freedom to estimate the within-group standard deviation. 
These formulas were also applied for the calculation of effect sizes from pretreatment to the 
latest follow-up.  
The controlled effect sizes were computed using the following formula:  
g = 	 (&'()&'*),(-(.()/0(*1(-*.()/0**-23456.* × 	 81 − ;<(=23456)>)?, 
such that	!' 1 is the mean of the treatment group, !"2  is the mean of the control group at 
posttreatment, SD1 and SD2 are the standard deviations of post-treatment scores of the 
treatment and control group, n is the sample size. This formula was also applied for the 
calculation of effect sizes from posttreatment to the latest follow-up. 
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